Dr. Moulin is a Senior Reviewer in the Division of Urology, Obstetrics and Gynecology within the Center for Drug Evaluation and Research of the US Food and Drug Administration. He holds a Doctorate in Veterinary Medicine from the Veterinary School of Lyon, France and a Doctorate in Pharmacology and Toxicology from Michigan State University. Dr. Moulin is a board-certified toxicologist and trained as a postdoctoral fellow at the Chemical Industry Institute of Toxicology. Before joining the FDA, Dr. Moulin worked for 13 years in Discovery Toxicology at Bristol-Myers Squibb, where he supported the safety assessment of new molecular entities in cardiovascular, neuroscience, antiviral and metabolic diseases. Dr. Moulin has been a scientific advisor on nonclinical prediction of drug-induced liver injury for the Predictive Safety Testing Consortium, the European Centre for the Validation of Alternative Methods, the MIP-DILI consortium and now the FDA Liver Toxicity Working Group.